Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells

Human Mutation

Volumn 33, Issue 8, 2012, Pages 1216-1227

  Salhia, Bodour ^a   Van Cott, Courtney ^a   Tegeler, Tony ^a   Polpitiya, Ashoka ^a   Duquette, Rachelle A ^a   Gale, Molly ^a   Hostteter, Galen ^a,b   Petritis, Konstantinos ^a   Carpten, John ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

AKT1; Breast cancer; Mammary luminal epithelial cells; Mammary myoepithelial cells

Indexed keywords

AKT1 PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; WILD TYPE;

BLOTTING, WESTERN; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPITHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, HUMAN; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84863863621     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22100     Document Type: Article

References (58)

1. Accili D, Arden KC. 2004. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421-426.
2. Bellacosa A, Testa JR, Moore R, Larue L. 2004. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther 3:268-275.
3. Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schonbrunn E, Cheng JQ, et al. 2010. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 17:1795-1804.
4. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, et al. 2008. AKT1(E17K) in human solid tumours. Oncogene 27:5648-5650.
5. Bleeker FE, Lamba S, Zanon C, van Tilborg AA, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Bardelli A. 2009. Absence of AKT1 mutations in glioblastoma. PloS One 4:e5638.
6. Cao Z, Song JH, Kim CJ, Cho YG, Kim SY, Nam SW, Lee JY, Park WS. 2008. Absence of E17K mutation in the pleckstrin homology domain of AKT1 in gastrointestinal and liver cancers in the Korean population. APMIS 116:530-533.
7. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, et al. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
8. Cordin O, Banroques J, Tanner NK, Linder P. 2006. The DEAD-box protein family of RNA helicases. Gene 367:17-37.
9. Dillon RL, White DE, Muller WJ. 2007. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 26:1338-1345.
10. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. 2008. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 1:14.
11. Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML. 2010. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120:409-418.
12. Falke JJ. 2007. Membrane Recruitment as a Cancer Mechanism: a case study of Akt PH domain. Cellscience 4:25-30.
13. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. 2004. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204.
14. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. 2004. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 94:785-795.
15. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD. 2007. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404:15-21.
16. Grandage VL, Gale RE, Linch DC, Khwaja A. 2005. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19:586-594.
17. Harris RA, Eichholtz TJ, Hiles ID, Page MJ, O'Hare MJ. 1999. New model of ErbB-2 over-expression in human mammary luminal epithelial cells. International journal of cancer. J Int Cancer 80:477-484.
18. Helm M. 2006. Post-transcriptional nucleotide modification and alternative folding of RNA. Nucleic Acids Res 34:721-733.
19. Holmstrom TH, Mialon A, Kallio M, Nymalm Y, Mannermaa L, Holm T, Johansson H, Black E, Gillespie D, Salminen TA, et al. 2008. c-Jun supports ribosomal RNA processing and nucleolar localization of RNA helicase DDX21. J Biol Chem 283:7046-7053.
20. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. 2007. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12:160-170.
21. Jo H, Lo PK, Li Y, Loison F, Green S, Wang J, Silberstein LE, Ye K, Chen H, Luo HR. 2011. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc Natl Acad Sci USA 108:6486-6491.
22. Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, et al. 2007. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA 104:7438-7443.
23. Kim MS, Jeong EG, Yoo NJ, Lee SH. 2008. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98:1533-1535.
24. Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. 2010. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem 285:8383-8394.
25. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM. 2005. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146.
26. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. 2003. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22:3205-3212.
27. Lakhani SR, Chaggar R, Davies S, Jones C, Collins N, Odel C, Stratton MR, O'Hare MJ. 1999. Genetic alterations in 'normal' luminal and myoepithelial cells of the breast. J Pathol 189:496-503.
28. Landgraf KE, Pilling C, Falke JJ. 2008. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47:12260-12269.
29. Larance M, Rowland AF, Hoehn KL, Humphreys DT, Preiss T, Guilhaus M, James DE. 2010. Global phosphoproteomics identifies a major role for AKT and 14-3-3 in regulating EDC3. Mol Cell Proteomics 9:682-694.
30. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, et al. 2010. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29:2337-2345.
31. Lee MW, Kim DS, Min NY, Kim HT. 2008. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 122:2380-2384.
32. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. 2003. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2:353-360.
33. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, et al. 2011. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 365:611-619.
34. Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA, Bissell MJ. 2006. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci USA 103:4134-419.
35. Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, Ismail SI. 2008. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99:488-490.
36. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, Malara N, Savino R, Rocco G, Chiappetta G, et al. 2008. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7:665-669.
37. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
38. Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM. 2008. AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat 7:407-408.
39. Nicholson KM, Anderson NG. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381-395.
40. Osaki M, Oshimura M, Ito H. 2004. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676.
41. Paez J, Sellers WR. 2003. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 115:145-167.
42. Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, Zvelebil MJ, Stein RC, Waterfield MD, Davies SC, et al. 1999. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA 96:12589-12594.
43. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
44. Pilling C, Landgraf KE, Falke JJ. 2011. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3, 4, 5)P(3). Biochemistry 50:9845-9856.
45. Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN, Camp DG, 2nd, Anderson GA, Smith RD. 2008. DAnTE: a statistical tool for quantitative analysis of -omics data. Bioinformatics 24:1556-1558.
46. Salhia B, Tran NL, Chan A, Wolf A, Nakada M, Rutka F, Ennis M, McDonough WS, Berens ME, Symons M, et al. 2008. The guanine nucleotide exchange factors trio, Ect2, and Vav3 mediate the invasive behavior of glioblastoma. Am J Pathol 173:1828-1838.
47. Schmelzle T, Hall MN. 2000. TOR, a central controller of cell growth. Cell 103:253-262.
48. Sen P, Mukherjee S, Ray D, Raha S. 2003. Involvement of the Akt/PKB signaling pathway with disease processes. Mol Cell Biochem 253:241-246.
49. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
50. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al. 2008. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091.
51. Testa JR, Bellacosa A. 2001. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983-10985.
52. Thompson A, Schafer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C. 2003. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 75:1895-1904.
53. Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, et al. 2010. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 23:27-37.
54. Vasudevan KM, Garraway LA. 2010. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 347:105-133.
55. Vichai V, Kirtikara K. 2006. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116.
56. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501.
57. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. 2005. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20:539-550.
58. Zenz T, Dohner K, Denzel T, Dohner H, Stilgenbauer S, Bullinger L. 2008. Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol 141:742-743.